Astec LifeSciences Limited
ASTEC · NSE · Basic Materials
With a 20% margin of safety, our buy-below price is ₹315.96. Low-confidence estimate — limited data.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-25.8%
- ✕Low debt (D/E < 0.5)1.15x
- ✕Positive free cash flow
- ✓Revenue growth > 10%33%
- –Earnings growing
- ✕Net margin ≥ 10%-18.1%
- ✕Current ratio > 1.50.89
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.05
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (-25.8%).
- •Weak Piotroski score (3/9).
Opportunities
- •Revenue growing (33% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~50% above our estimated fair value.
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and f
More in Basic Materials
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.